Trials / Unknown
UnknownNCT01473459
Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome Patients
Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Hillel Yaffe Medical Center · Other Government
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare two fertility protocols in obese women with Polycystic Ovarian Syndrome who are candidates for In Vitro Fertilization (IVF). These protocols carry less risk of ovarian hyperstimulation syndrome which these women may experience.
Detailed description
The purpose of this study is to compare two fertility protocols in obese women with Polycystic Ovarian Syndrome who are candidates for In Vitro Fertilization (IVF). These protocols carry less risk of ovarian hyperstimulation syndrome which these women may experience.The patients in the IVM group will not be exposeD to gonadotropin treatment for controlled ovarian hyperstimulation. In the antagonist group we will use GnRH agonist to induce ovulation which may reduce the risk for ovarian hyperstimulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | IVM (In Vitro Maturation) Treatment | There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3. |
| PROCEDURE | IVF (In Vitro Fertilization) Antagonist Protocol | The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3. |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2013-01-01
- Completion
- 2013-01-01
- First posted
- 2011-11-17
- Last updated
- 2012-04-26
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01473459. Inclusion in this directory is not an endorsement.